Compare Amphastar Pharmaceuticals Inc (AMPH) vs Blackstone Inc (BX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Blackstone (BX) trades at $123.08, up 0.78% with a bullish technical signal. The stock shows strong fundamentals with revenue growth to $12.41B in 2025 and consistent earnings beats. Recent news highlights strategic moves in data centers and private equity, while analyst consensus is strongly bullish with a $147.44 price target.

Outlook remains positive driven by earnings momentum and strategic investments, though risks include market volatility and execution challenges. The current valuation at 31.56 P/E suggests premium pricing, requiring sustained growth to justify upside potential.